Colchicine-induced neuromyopathy in a patient with chronic renal failure: The role of clarithromycin

Netherlands Journal of Medicine

Volumn 66, Issue 5, 2008, Pages 204-206

  van der Velden, W ^a   Huussen, J ^a,b   ter Laak, H ^a   de Sevaux R ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SLINGELAND HOSPITAL   (Netherlands)

Author keywords

Clarithromycin; Colchicine; CYP3A4; Neuromyopathy; P glycoprotein; Simvastatin

Indexed keywords

ALLOPURINOL; CLARITHROMYCIN; COLCHICINE; SIMVASTATIN;

AGED; ARTICLE; ATHEROSCLEROSIS; CASE REPORT; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; GOUT; HUMAN; HYPERTENSION; MALE; MUSCLE BIOPSY; MUSCLE NECROSIS; MYALGIA; NEUROMUSCULAR DISEASE; PNEUMONIA; SKIN DISEASE; VASCULITIS;

AGED; ANTI-BACTERIAL AGENTS; ANTICHOLESTEREMIC AGENTS; CLARITHROMYCIN; COLCHICINE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; NEUROMUSCULAR DISEASES; P-GLYCOPROTEIN; RISK FACTORS; SIMVASTATIN; TUBULIN MODULATORS;

EID: 44649091266     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Caglar K, Odabasi Z, Safali M, Yenicesu M, Vural A. Colchicine-induced myopathy with myotonia in a patient with chronic renal failure. Clin Neurol Neurosurg 2003;105:274-6.
2. Dupont P, Hunt I, Goldberg L, Warrens A. Colchicine myoneuropathy in a renal transplant patient. Transpl Int 2002;15:374-6.
3. Medical Research Council. Aids to the investigation of the peripheral nervous system. London: Her Majesty's Stationary Office 1975;1-2.
4. Prueksaritanont T, Vega JM, Rogers JD, et al. Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects. J Clin Pharmacol 2000;40:1274-9.
5. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther 2002;303:323-32.
6. Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ. Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation. Biochem Pharmacol 1997;53:111-6.
7. Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K. Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure. J Nephrol 2006;19:515-7.
8. Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P. Acute colchicine intoxication during clarithromycin administration. Ann Pharmacother 2004;38:2074-7.
9. Hung IF, Wu AK, Cheng VC, et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis 2005;41:291-300.
10. Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol 1991;18:264-9.
11. Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and literature review. Pharmacotherapy 2004;24:1784-92.
12. Kuncl RW, Bilak MM, Craig SW, Adams R. Exocytotic "constipation" is a mechanism of tubulin/lysosomal interaction in colchicine myopathy. Exp Cell Res 2003;285:196-207.
13. Chappey O, Scherrmann JM. Colchicine: recent data on pharmacokinetics and clinical pharmacology. Rev Med Intern 1995;16:782-9.